1. The plaintiffs' claims are dismissed.

2. The costs of lawsuit are assessed against the plaintiffs.

1. Basic facts

A. 1) The title of the instant patent invention: The date of claiming a priority (hereinafter referred to as “priority date”) for the treatment of pain and its ethyl 2).

/ International filing date/registration date/registration number: July 24, 1996/ July 16, 1997/ May 16, 2005/0491282

B. 1) The Plaintiffs and the non-party 1 companies, Korea Tyd Co., Ltd., the closing party to the case, and the non-party 1 companies, both of which filed a lawsuit seeking the invalidation trial of the instant patent invention against the Defendant. The grounds for filing a petition for the invalidation trial of the instant patent invention against the Intellectual Property Tribunal were neither written nor non-obviousness nor non-obviousness. 2) The Defendant filed a request for correction with respect to the correction of the instant patent invention claims 1 and deletion of claims 2 and 3 in the instant trial proceeding.

3) The Korean Intellectual Property Tribunal rendered a trial ruling on the foregoing cases (each of the foregoing cases as follows: (a) and on the following cases:

Therefore, the corrected patented invention of this case is construed as “the corrected invention of this case,” and the corrected claim 1 is referred to as “the corrected invention of this case 1,” and the remainder of the claims are also described in the same manner.

B) The instant appeal is dismissed (the fact that there is no dispute over the grounds for recognition, Gap evidence Nos. 1 and 2, Gap evidence No. 3-1 and 2, and the purport of the entire pleadings).

2. The key point of the Plaintiffs’ assertion is that the corrective invention of this case refers to the 3-(amaminoethyl)-5-methyl acid e.g. (S)-3-(ammethyl)-5-methyl acid e.g., (S) e., ethyl acid.

As to the invention of use as to the authenticity effect, since the authenticity effect of press release can be easily derived for the following reasons, this case's trial decision, which judged otherwise, despite the non-obviousness of the registration, should be invalidated, asserts that this case's trial decision is unlawful.

GABABA: the weak in gamma-minabruutyricida

Representative suppressions.